伊布替尼治疗异基因造血干细胞移植后晚期复发慢性淋巴细胞白血病的疗效 - Suppr

Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.

作者信息

Innocenti Idanna, Sora Federica, Autore Francesco, Chiusolo Patrizia, Giammarco Sabrina, Metafuni Elisabetta, Bacigalupo Andrea, Sica Simona, Laurenti Luca

机构信息

Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.

Dipartimento di Scienze Radiologiche ed Ematologiche, Sezione di Ematologia, Università Cattolica del Sacro Cuore, Roma, Italy.

出版信息

Hematol Oncol. 2021 Apr;39(2):267-269. doi: 10.1002/hon.2826. Epub 2020 Nov 20.

DOI:10.1002/hon.2826

PMID:33150962

Abstract

摘要

相似文献

Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.

Hematol Oncol. 2021 Apr;39(2):267-269. doi: 10.1002/hon.2826. Epub 2020 Nov 20.

Successful ibrutinib treatment for central nervous system relapse of chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.

Ann Hematol. 2022 Mar;101(3):723-724. doi: 10.1007/s00277-021-04586-w. Epub 2021 Jul 8.

Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia.

Haematologica. 2019 May;104(5):e224-e226. doi: 10.3324/haematol.2018.212837. Epub 2019 Feb 21.

What Influences the Choice of Ibrutinib-Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?

Cell Transplant. 2020 Jan-Dec;29:963689720950209. doi: 10.1177/0963689720950209.

Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.

Blood. 2016 Dec 22;128(25):2899-2908. doi: 10.1182/blood-2016-06-715284. Epub 2016 Nov 1.

Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia.

Bone Marrow Transplant. 2020 May;55(5):884-890. doi: 10.1038/s41409-019-0742-7. Epub 2019 Nov 7.

Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients.

Leukemia. 2021 Nov;35(11):3287-3290. doi: 10.1038/s41375-021-01237-x. Epub 2021 Apr 5.

Transformation to plasmablastic lymphoma in CLL upon ibrutinib treatment.

BMJ Case Rep. 2020 Sep 29;13(9):e235816. doi: 10.1136/bcr-2020-235816.

Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia.

Curr Med Res Opin. 2020 Dec;36(12):2009-2018. doi: 10.1080/03007995.2020.1835851. Epub 2020 Oct 29.

Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties.

Bone Marrow Transplant. 2019 Jan;54(1):44-52. doi: 10.1038/s41409-018-0207-4. Epub 2018 May 4.

引用本文的文献

Successful ibrutinib treatment for central nervous system relapse of chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.

Ann Hematol. 2022 Mar;101(3):723-724. doi: 10.1007/s00277-021-04586-w. Epub 2021 Jul 8.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.

作者信息

Innocenti Idanna, Sora Federica, Autore Francesco, Chiusolo Patrizia, Giammarco Sabrina, Metafuni Elisabetta, Bacigalupo Andrea, Sica Simona, Laurenti Luca

机构信息

Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Roma, Italy.

Dipartimento di Scienze Radiologiche ed Ematologiche, Sezione di Ematologia, Università Cattolica del Sacro Cuore, Roma, Italy.

出版信息

Hematol Oncol. 2021 Apr;39(2):267-269. doi: 10.1002/hon.2826. Epub 2020 Nov 20.

DOI:10.1002/hon.2826

PMID:33150962

Abstract

摘要

相似文献

Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.

Hematol Oncol. 2021 Apr;39(2):267-269. doi: 10.1002/hon.2826. Epub 2020 Nov 20.

Successful ibrutinib treatment for central nervous system relapse of chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.

Ann Hematol. 2022 Mar;101(3):723-724. doi: 10.1007/s00277-021-04586-w. Epub 2021 Jul 8.

Venetoclax plus rituximab or obinutuzumab after allogeneic hematopoietic stem cell transplantation in chronic lymphocytic leukemia.

Haematologica. 2019 May;104(5):e224-e226. doi: 10.3324/haematol.2018.212837. Epub 2019 Feb 21.

What Influences the Choice of Ibrutinib-Rituximab vs Classic Chemoimmunotherapy for Chronic Lymphocytic Leukemia?

Cell Transplant. 2020 Jan-Dec;29:963689720950209. doi: 10.1177/0963689720950209.

Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT.

Blood. 2016 Dec 22;128(25):2899-2908. doi: 10.1182/blood-2016-06-715284. Epub 2016 Nov 1.

Ibrutinib as a salvage therapy after allogeneic HCT for chronic lymphocytic leukemia.

Bone Marrow Transplant. 2020 May;55(5):884-890. doi: 10.1038/s41409-019-0742-7. Epub 2019 Nov 7.

Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients.

Leukemia. 2021 Nov;35(11):3287-3290. doi: 10.1038/s41375-021-01237-x. Epub 2021 Apr 5.

Transformation to plasmablastic lymphoma in CLL upon ibrutinib treatment.

BMJ Case Rep. 2020 Sep 29;13(9):e235816. doi: 10.1136/bcr-2020-235816.

Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia.

Curr Med Res Opin. 2020 Dec;36(12):2009-2018. doi: 10.1080/03007995.2020.1835851. Epub 2020 Oct 29.

Bone Marrow Transplant. 2019 Jan;54(1):44-52. doi: 10.1038/s41409-018-0207-4. Epub 2018 May 4.

引用本文的文献

Successful ibrutinib treatment for central nervous system relapse of chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.

Ann Hematol. 2022 Mar;101(3):723-724. doi: 10.1007/s00277-021-04586-w. Epub 2021 Jul 8.

Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Efficacy of ibrutinib in late relapse chronic lymphocytic leukemia after allogeneic hematopoietic stem cell transplantation.

作者信息

机构信息

出版信息

相似文献

引用本文的文献